Our pathway analysis of simvastatin-treated PBMCs also identified upregulation of signaling pathways regulated by AMPK, a serine-threonine kinase that inhibits mTORC1 signaling and induces autophagy (62), and upregulated liver kinase B1 (LKB1), a serine-threonine kinase that activates AMPK (63) (Table 2), as previously observed in squamous cell carcinoma (64). The gene discussed is MARK2; the disease is squamous cell carcinoma.